Trial Profile

Phase Ia first in human randomized, double-blind, placebo-controlled trial assessed the safety, tolerability and pharmacokinetics (PK) of single and multiple ascending doses of THN391 in healthy volunteers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 06 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs THN 391 (Primary)
Indications Alzheimer's disease; Hyperlipidaemia; Hypertension; Type 2 diabetes mellitus
Focus Adverse reactions; First in man
Sponsors Therini Bio

29 Apr 2025 Results presented in the Therini Bio media release.
29 Apr 2025 According to Therini Bio media release, the company announced the data from this study will be presented at the Alzheimer's Association International Conference 2025 (AAIC 25) in Toronto, Canada, on Wednesday, July 30, 2025.
24 Oct 2023 According to Therini Bio media release, the interim data will be detailed in a poster presentation at the 16th Clinical Trials on Alzheimer's Disease (CTAD) conference taking place from October 25-27, 2023, in Boston, MA.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com